CN115605595A - 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用 - Google Patents
生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用 Download PDFInfo
- Publication number
- CN115605595A CN115605595A CN202080099055.6A CN202080099055A CN115605595A CN 115605595 A CN115605595 A CN 115605595A CN 202080099055 A CN202080099055 A CN 202080099055A CN 115605595 A CN115605595 A CN 115605595A
- Authority
- CN
- China
- Prior art keywords
- survivin
- csf
- tumor
- amino acid
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010002687 Survivin Proteins 0.000 title claims abstract description 94
- 102000000763 Survivin Human genes 0.000 title claims abstract description 85
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title claims abstract description 81
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title claims abstract description 75
- 229960005486 vaccine Drugs 0.000 title claims abstract description 51
- 230000004927 fusion Effects 0.000 title claims abstract description 36
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 25
- 239000013604 expression vector Substances 0.000 title claims abstract description 21
- 238000003259 recombinant expression Methods 0.000 title claims abstract description 15
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims abstract description 66
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 21
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 21
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000013605 shuttle vector Substances 0.000 claims description 4
- 241000588722 Escherichia Species 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 20
- 108091007433 antigens Proteins 0.000 abstract description 20
- 102000036639 antigens Human genes 0.000 abstract description 20
- 230000005847 immunogenicity Effects 0.000 abstract description 13
- 239000002671 adjuvant Substances 0.000 abstract description 12
- 229940126585 therapeutic drug Drugs 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 49
- 239000013612 plasmid Substances 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 22
- 239000000047 product Substances 0.000 description 19
- 239000000499 gel Substances 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000012546 transfer Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000010412 perfusion Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000002033 PVDF binder Substances 0.000 description 10
- 239000006180 TBST buffer Substances 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000003292 glue Substances 0.000 description 10
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000029087 digestion Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000001976 enzyme digestion Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 7
- 229940097277 hygromycin b Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000002045 lasting effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000896234 Homo sapiens Baculoviral IAP repeat-containing protein 5 Proteins 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 102000047803 human BIRC5 Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000012257 pre-denaturation Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
生存素与GM‑CSF的融合体、编码DNA、重组表达载体、抗肿瘤疫苗及其应用。所述生存素与GM‑CSF的融合体包含可操作地连接的生存素和GM‑CSF。编码所述生存素与GM‑CSF的融合体的DNA包含可操作地连接的生存素编码元件和GM‑CSF编码元件，其中所述生存素编码元件编码生存素的氨基酸序列，所述GM‑CSF编码元件编码GM‑CSF的氨基酸序列。所述融合体有效提高了生存素蛋白的免疫原性，所构建的重组BCG疫苗同时联合发挥BCG疫苗载体和治疗药物的作用，实现抗原、佐剂和疫苗载体的协同作用，使得肿瘤疫苗的免疫原性达到更有效、更持久的发挥。
Description
PCT国内申请，说明书已公开。
Claims (13)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/074313 WO2021155501A1 (zh) | 2020-02-05 | 2020-02-05 | 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115605595A true CN115605595A (zh) | 2023-01-13 |
Family
ID=77199641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080099055.6A Pending CN115605595A (zh) | 2020-02-05 | 2020-02-05 | 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115605595A (zh) |
| WO (1) | WO2021155501A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111118063B (zh) * | 2019-12-05 | 2023-04-18 | 吉林大学 | 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101096680A (zh) * | 2007-05-31 | 2008-01-02 | 中国人民解放军军事医学科学院基础医学研究所 | 一种dna疫苗真核表达载体及其在制备基因疫苗中的应用 |
| CN101575607B (zh) * | 2009-04-28 | 2012-09-26 | 中国人民解放军第四军医大学 | 一种基于人muc1重复序列与gm-csf融合表达的重组卡介苗疫苗 |
| CN104013973A (zh) * | 2009-12-04 | 2014-09-03 | 长春百克生物科技股份公司 | 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗 |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| CN102181401B (zh) * | 2011-02-01 | 2013-04-24 | 北京市肿瘤防治研究所 | 存活素酶联免疫试剂盒及其应用 |
| CN102732543B (zh) * | 2011-04-07 | 2016-04-20 | 长春百克生物科技股份公司 | 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗 |
| EP2981284A1 (en) * | 2013-04-05 | 2016-02-10 | Kyushu University National University Corporation | Anti-tumor dna vaccine |
| CN103948944B (zh) * | 2013-05-20 | 2016-06-01 | 中国人民解放军军事医学科学院基础医学研究所 | 一种广谱抗肿瘤双质粒可复制型dna疫苗 |
-
2020
- 2020-02-05 CN CN202080099055.6A patent/CN115605595A/zh active Pending
- 2020-02-05 WO PCT/CN2020/074313 patent/WO2021155501A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021155501A1 (zh) | 2021-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021203608A1 (zh) | 靶向vegfr2的转移性癌疫苗 | |
| US11648306B2 (en) | Non-integrative listeria-based vaccine and method for inducing antitumor immune response | |
| CN112533939B (zh) | 一种基于减毒李斯特菌激活的抗原提呈细胞的肿瘤免疫治疗组合物、制备方法和应用 | |
| WO2014129412A1 (ja) | 免疫原性ポリペプチド表層発現ビフィズス菌 | |
| CN115605595A (zh) | 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用 | |
| CN114478715B (zh) | 一种减毒沙门氏菌分泌表达s2结构域蛋白的新型冠状病毒疫苗递呈系统及其应用 | |
| CN101575607B (zh) | 一种基于人muc1重复序列与gm-csf融合表达的重组卡介苗疫苗 | |
| KR20040104464A (ko) | 종양을 치료하기 위해 사용되는 세포 항원을 코딩하는뉴클레오티드 서열의 캐리어로서 기능하는 미생물 | |
| WO2017036026A1 (zh) | 基因修饰的间充质干细胞及其用于生产BsAb抗体的方法 | |
| WO2023142647A1 (zh) | 一种新型hpv治疗性核酸疫苗 | |
| CN111349645B (zh) | 一种提高非整合减毒李斯特菌疫苗安全性的方法 | |
| CN111334521B (zh) | 一种提高非整合减毒李斯特菌外源抗原蛋白表达的方法 | |
| CN109568574B (zh) | sPD1蛋白和/或sPD1基因作为免疫佐剂的应用 | |
| CN105343874A (zh) | 一种前列腺癌核酸疫苗 | |
| CN111118063A (zh) | 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用 | |
| JP4459060B2 (ja) | ポリヌクレオチドからなるワクチン | |
| CN109081873B (zh) | 一种抗肿瘤重组nmm融合抗原质粒dna疫苗 | |
| CN110172480B (zh) | 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用 | |
| CN113943689B (zh) | 一种免疫激活性重组乳酸乳球菌的构建及作为肿瘤疫苗和免疫佐剂等方面的应用 | |
| CN107557338A (zh) | 特异性识别ny‑eso‑1的t细胞及其与细胞因子的联合的应用 | |
| CN114790248B (zh) | MUC1-PDL1-IgG1 Fc肿瘤疫苗及其制备方法和应用 | |
| CN113372453B (zh) | 一种融合蛋白及猪流行性腹泻病毒s1蛋白重组亚单位疫苗 | |
| CN113684214B (zh) | 一种基于减毒李斯特菌的肿瘤疫苗的制备和应用 | |
| CN105985444A (zh) | 一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用 | |
| CN116948038A (zh) | 用于诱导肿瘤特异性免疫应答的重组抗原肽及重组李斯特菌 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |